期刊
ONCOIMMUNOLOGY
卷 1, 期 3, 页码 371-373出版社
LANDES BIOSCIENCE
DOI: 10.4161/onci.18963
关键词
NK cells; activating receptors; lenalidomide; dexamethasone; myeloma
Dexamethasone has been a mainstay of anti-myeloma therapy for 20 years. However, it is intensely immunosuppressive and may limit the efficacy of the immune system to control myeloma, and limit the exciting opportunities to use immune stimulating drug therapies such as Lenalidomide to maximize the fight against this disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据